IGM Biosciences Appoints Lisa Decker, Ph.D., as Chief Business Officer
March 15, 2021 07:00 ET
|
IGM Biosciences
MOUNTAIN VIEW, Calif., March 15, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (IGM), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today...
IGM Biosciences to Present at the Guggenheim Healthcare Talks 2021 Idea Forum Oncology Day
February 05, 2021 07:00 ET
|
IGM Biosciences
MOUNTAIN VIEW, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies,...
IGM Biosciences Enters into Exclusive Licensing Agreement with Medivir for Birinapant
January 11, 2021 18:00 ET
|
IGM Biosciences
MOUNTAIN VIEW, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS) today announced that it has entered into an exclusive license agreement with Medivir AB (Nasdaq...
IGM Biosciences to Present at the 39th Annual J.P. Morgan Healthcare Conference
January 07, 2021 07:00 ET
|
IGM Biosciences
MOUNTAIN VIEW, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies,...
IGM Announces Closing of $230 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
December 11, 2020 16:05 ET
|
IGM Biosciences
MOUNTAIN VIEW, Calif., Dec. 11, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ: IGMS) (IGM) today announced the closing of its upsized underwritten public offering of 1,221,224 shares of its...
IGM Announces Pricing of Upsized $200 million Public Offering
December 08, 2020 22:30 ET
|
IGM Biosciences
MOUNTAIN VIEW, Calif., Dec. 08, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ: IGMS) (IGM) today announced the pricing of its upsized underwritten public offering of shares of its common...
IGM Announces Proposed Public Offering
December 07, 2020 17:07 ET
|
IGM Biosciences
MOUNTAIN VIEW, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ: IGMS) today announced that it intends to offer and sell $150 million of shares of its common stock and, in...
IGM Biosciences Presents First Clinical Data from IGM-2323 in Non-Hodgkin’s Lymphoma at 2020 ASH Annual Meeting
December 05, 2020 13:30 ET
|
IGM Biosciences
- 9 of 14 Patients Showed Reduction in Tumor Size, Including Two Recently Reported Complete Responses - - Company to Host Conference Call and Webcast Today at 2:00 p.m. ET - MOUNTAIN VIEW,...
IGM Biosciences to Host Conference Call and Webcast to Review IGM-2323 Data Presented at the 62nd Annual ASH Meeting
November 30, 2020 07:00 ET
|
IGM Biosciences
MOUNTAIN VIEW, Calif., Nov. 30, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies,...
IGM Biosciences to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference
November 23, 2020 07:00 ET
|
IGM Biosciences
MOUNTAIN VIEW, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies,...